AI Engines For more Details: Perplexity Kagi Labs You
Hypertension (High Blood Pressure): Nadolol is effective in lowering blood pressure levels by reducing the workload on the heart and relaxing blood vessels. By blocking the action of adrenaline (epinephrine) on the heart and blood vessels, nadolol helps to decrease the heart rate and dilate blood vessels, thereby lowering blood pressure. It is often prescribed as a first-line treatment for hypertension and may be used alone or in combination with other antihypertensive medications.
Angina Pectoris: Nadolol may be used to prevent episodes of angina pectoris, a type of chest pain caused by reduced blood flow to the heart muscle. By reducing the heart rate and workload on the heart, nadolol helps to decrease oxygen demand by the heart, thereby preventing or reducing the severity and frequency of angina attacks.
Arrhythmias: Nadolol is also indicated for the management of certain heart rhythm disorders, particularly supraventricular tachycardias (SVTs) such as atrial fibrillation and atrial flutter. By slowing down the heart rate and stabilizing the heart's electrical activity, nadolol can help to control abnormal heart rhythms and reduce the risk of complications associated with these conditions.
Migraine Prophylaxis: In some cases, nadolol may be prescribed off-label for the prevention of migraine headaches. The exact mechanism by which nadolol exerts its migraine-preventive effects is not fully understood, but it is believed to involve its ability to reduce the excitability of neurons and alter the transmission of pain signals in the brain. Nadolol may help to reduce the frequency and severity of migraine attacks in certain individuals.
Essential Tremor: Nadolol has been used off-label for the treatment of essential tremor, a neurological disorder characterized by involuntary shaking of the hands, arms, head, voice, or other parts of the body. Nadolol's beta-blocking properties may help to reduce tremor severity by stabilizing the activity of certain neurotransmitters in the brain.
Portal Hypertension: Nadolol may also be used off-label in the management of portal hypertension, a condition characterized by high blood pressure in the portal vein system that carries blood from the digestive organs to the liver. By reducing portal vein pressure, nadolol can help to prevent complications such as variceal bleeding in individuals with cirrhosis or other liver diseases.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 1.4 | 0.6 | 1.33 |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.5 | |
| Allergic Rhinitis (Hay Fever) | 1.4 | 0.5 | 1.8 |
| Allergies | 2.4 | 1.9 | 0.26 |
| Allergy to milk products | 1.4 | 1.2 | 0.17 |
| Alopecia (Hair Loss) | 0.3 | 0.3 | |
| Alzheimer's disease | 2.5 | 3.9 | -0.56 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.3 | 0.4 | 2.25 |
| Ankylosing spondylitis | 1.8 | 0.6 | 2 |
| Anorexia Nervosa | 0.8 | 1.5 | -0.88 |
| Antiphospholipid syndrome (APS) | 0.1 | 0.3 | -2 |
| Asthma | 1.9 | 1.5 | 0.27 |
| Atherosclerosis | 1.4 | 0.7 | 1 |
| Atrial fibrillation | 1.6 | 1.5 | 0.07 |
| Autism | 3.7 | 3.5 | 0.06 |
| Autoimmune Disease | 0.9 | 1 | -0.11 |
| Barrett esophagus cancer | 0.3 | 0.3 | |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 0.3 | 0.3 | |
| Bipolar Disorder | 2 | 1.7 | 0.18 |
| Brain Trauma | 0.6 | 1.4 | -1.33 |
| Breast Cancer | 0.1 | 0.1 | |
| Cancer (General) | 0.3 | 0.7 | -1.33 |
| Carcinoma | 2.3 | 1.2 | 0.92 |
| Celiac Disease | 0.8 | 1.5 | -0.88 |
| Cerebral Palsy | 1.1 | 1.1 | 0 |
| Chronic Fatigue Syndrome | 2.6 | 2.4 | 0.08 |
| Chronic Kidney Disease | 1.9 | 1.5 | 0.27 |
| Chronic Lyme | 0.8 | -0.8 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.6 | 1.1 | -0.83 |
| Chronic Urticaria (Hives) | 1.1 | 0.2 | 4.5 |
| Coagulation / Micro clot triggering bacteria | 0.7 | 0.8 | -0.14 |
| Cognitive Function | 1.2 | 1 | 0.2 |
| Colorectal Cancer | 2.7 | 1.7 | 0.59 |
| Constipation | 1.2 | 0.5 | 1.4 |
| Coronary artery disease | 1.2 | 1.5 | -0.25 |
| COVID-19 | 2.9 | 3.3 | -0.14 |
| Crohn's Disease | 3.9 | 2.1 | 0.86 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 0.7 | 1.2 | -0.71 |
| d-lactic acidosis (one form of brain fog) | 0.1 | 0.1 | |
| deep vein thrombosis | 1.1 | 1.1 | 0 |
| Denture Wearers Oral Shifts | 0.2 | 0.2 | |
| Depression | 4 | 3.8 | 0.05 |
| Dermatomyositis | 0.3 | -0.3 | |
| Eczema | 1.1 | 0.7 | 0.57 |
| Endometriosis | 1.5 | 1.5 | 0 |
| Eosinophilic Esophagitis | 0.3 | -0.3 | |
| Epilepsy | 1.7 | 0.6 | 1.83 |
| erectile dysfunction | 1.1 | 0.3 | 2.67 |
| Fibromyalgia | 1.3 | 1.1 | 0.18 |
| Functional constipation / chronic idiopathic constipation | 2.3 | 2.3 | 0 |
| gallstone disease (gsd) | 1.6 | 0.8 | 1 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.4 | 0.4 | |
| Generalized anxiety disorder | 1.5 | 1.1 | 0.36 |
| giant cell arteritis | 0.2 | -0.2 | |
| Gout | 1 | 0.5 | 1 |
| Graves' disease | 1.5 | 2.3 | -0.53 |
| Gulf War Syndrome | 0.5 | 0.4 | 0.25 |
| Halitosis | 0.6 | 0.6 | |
| Hashimoto's thyroiditis | 1.9 | 0.9 | 1.11 |
| Heart Failure | 1.7 | 1.1 | 0.55 |
| Hidradenitis Suppurativa | 0.6 | 0.3 | 1 |
| High Histamine/low DAO | 0.8 | 0.6 | 0.33 |
| hypercholesterolemia (High Cholesterol) | 0.3 | 0.3 | |
| hyperglycemia | 0.9 | 0.6 | 0.5 |
| Hyperlipidemia (High Blood Fats) | 0.9 | 0.3 | 2 |
| hypersomnia | 0.6 | -0.6 | |
| hypertension (High Blood Pressure | 1.8 | 2.4 | -0.33 |
| Hypothyroidism | 0.9 | -0.9 | |
| Hypoxia | 1.4 | 0.3 | 3.67 |
| IgA nephropathy (IgAN) | 0.9 | 1.7 | -0.89 |
| Inflammatory Bowel Disease | 2.7 | 4.1 | -0.52 |
| Insomnia | 0.9 | 1.4 | -0.56 |
| Intelligence | 0.8 | 0 | 0 |
| Intracranial aneurysms | 0.6 | 0.6 | 0 |
| Irritable Bowel Syndrome | 3.4 | 2.6 | 0.31 |
| ischemic stroke | 1.3 | 1.4 | -0.08 |
| Liver Cirrhosis | 3.9 | 2.5 | 0.56 |
| Long COVID | 2.6 | 3.3 | -0.27 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 1 | 0.3 | 2.33 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 0.6 | 0.9 | -0.5 |
| ME/CFS with IBS | 0.3 | 0.9 | -2 |
| ME/CFS without IBS | 0.6 | 0.6 | 0 |
| Menopause | 0.2 | 0.5 | -1.5 |
| Metabolic Syndrome | 4.6 | 3.3 | 0.39 |
| Mood Disorders | 4.1 | 4 | 0.02 |
| multiple chemical sensitivity [MCS] | 0.3 | 0.3 | |
| Multiple Sclerosis | 2.3 | 2.1 | 0.1 |
| Multiple system atrophy (MSA) | 0.1 | 0.6 | -5 |
| myasthenia gravis | 0.6 | 0.7 | -0.17 |
| neuropathic pain | 0.3 | 1.3 | -3.33 |
| Neuropathy (all types) | 0.3 | 1.1 | -2.67 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.1 | 0.1 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.4 | 1.9 | 0.26 |
| NonCeliac Gluten Sensitivity | 1.2 | 0.6 | 1 |
| Obesity | 4.1 | 3.3 | 0.24 |
| obsessive-compulsive disorder | 2.1 | 1 | 1.1 |
| Osteoarthritis | 1.1 | 0.9 | 0.22 |
| Osteoporosis | 2.5 | 0.3 | 7.33 |
| Parkinson's Disease | 4.2 | 3.4 | 0.24 |
| Polycystic ovary syndrome | 3.3 | 2.5 | 0.32 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.6 | 0.6 | |
| primary biliary cholangitis | 0.3 | 0.5 | -0.67 |
| Primary sclerosing cholangitis | 1 | 0.8 | 0.25 |
| Psoriasis | 1.5 | 1.2 | 0.25 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 4.1 | 2.3 | 0.78 |
| Rosacea | 0.6 | 0.7 | -0.17 |
| Schizophrenia | 2.9 | 2.2 | 0.32 |
| scoliosis | 0.3 | 0.6 | -1 |
| Sjögren syndrome | 1.1 | 0.7 | 0.57 |
| Sleep Apnea | 0.9 | 1.7 | -0.89 |
| Slow gastric motility / Gastroparesis | 0.9 | 0.3 | 2 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.1 | 0 | 0 |
| Stress / posttraumatic stress disorder | 1.4 | 1.8 | -0.29 |
| Systemic Lupus Erythematosus | 2.4 | 1.6 | 0.5 |
| Tic Disorder | 0.3 | 0.6 | -1 |
| Tourette syndrome | 0.3 | -0.3 | |
| Type 1 Diabetes | 2.5 | 2.1 | 0.19 |
| Type 2 Diabetes | 3.8 | 2.9 | 0.31 |
| Ulcerative colitis | 1.9 | 2.6 | -0.37 |
| Unhealthy Ageing | 1.7 | 1.1 | 0.55 |
| Vitiligo | 1 | 0.8 | 0.25 |
